169 related articles for article (PubMed ID: 3837249)
1. [Pharmacokinetics of oral theophylline. Comparison between asthmatic and cystic fibrosis patients].
Repetto T; Marianelli L; Valenza T; Rosselli P; Messori A
Pediatr Med Chir; 1985; 7(6):823-5. PubMed ID: 3837249
[TBL] [Abstract][Full Text] [Related]
2. Oral theophylline disposition in cystic fibrosis.
Georgitis JW; Eigen H; Warner R; Gonzales MA
Ann Allergy; 1982 Mar; 48(3):175-7. PubMed ID: 7065481
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis.
Valet SB; Schwartz RH; Brooks JG
Ann Allergy; 1983 Mar; 50(3):161-5. PubMed ID: 6829982
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of a short- and long-acting theophylline medication (theolair and Theolair retard) in normals and asthmatics. Part I: pharmacokinetics.
Utama I; Kreukniet J; Meering PG; Maes RA
Int J Clin Pharmacol Ther Toxicol; 1983 Jun; 21(6):287-91. PubMed ID: 6885202
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis.
Jones KM; Liao E; Hohneker K; Turpin S; Henry MM; Selinger K; Hsyu PH; Boucher RC; Knowles MR; Dukes GE
Pharmacotherapy; 1997; 17(2):263-70. PubMed ID: 9085317
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation.
Nosaka H; Takagi K; Hasegawa T; Ogura Y; Mizukami Y; Satake T
Int J Clin Pharmacol Ther Toxicol; 1986 Oct; 24(10):528-35. PubMed ID: 3781672
[TBL] [Abstract][Full Text] [Related]
7. [Adaptation of the oral dosage of theophylline to the asthmatic child. Value of a kinetic test by the intravenous route].
Albertini M; Lapalus P; Maurin S; Boutte P; Mariani R
Arch Fr Pediatr; 1982 Nov; 39(9):671-5. PubMed ID: 7165461
[TBL] [Abstract][Full Text] [Related]
8. Studies on the pharmacokinetics of theophylline and its effect on respiratory impedance in asthmatic patients after multiple oral dosing of a sustained-release theophylline tablet formulation.
Takagi K; Nosaka H; Satake T; Hasegawa T; Ogura Y; Mizukami Y
Arerugi; 1986 May; 35(5):320-8. PubMed ID: 3753206
[No Abstract] [Full Text] [Related]
9. Probenecid pharmacokinetics in cystic fibrosis.
Weber A; de Groot R; Ramsey B; Williams-Warren J; Smith A
Dev Pharmacol Ther; 1991; 16(1):7-12. PubMed ID: 1879255
[TBL] [Abstract][Full Text] [Related]
10. Theophylline disposition in cystic fibrosis.
Isles A; Spino M; Tabachnik E; Levison H; Thiessen J; MacLeod S
Am Rev Respir Dis; 1983 Apr; 127(4):417-21. PubMed ID: 6838048
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic properties of a new sustained-release theophylline preparation.
Dahlqvist R; Billing B
Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):69-72. PubMed ID: 6840927
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of etofylline after intravenous and oral administration to humans.
Zuidema J; Verhoeven J; Merkus FW
Int J Clin Pharmacol Ther Toxicol; 1981 Jul; 19(7):310-3. PubMed ID: 7263108
[TBL] [Abstract][Full Text] [Related]
13. Studies on the pharmacokinetics of theophylline in asthmatic patients following multiple oral dosing of a sustained-release theophylline tablet formulation.
Takagi K; Yamaki K; Satake T; Hasegawa T; Ogura Y; Suzuki R; Mizukami Y
Arerugi; 1985 Nov; 34(11):1006-14. PubMed ID: 4084062
[No Abstract] [Full Text] [Related]
14. [Pharmacokinetics of a new slow-release theophylline preparation in asthmatic children].
Nieto A; Mazón A; Caballero L; Gil MC
An Esp Pediatr; 1985 Apr; 22(5):383-92. PubMed ID: 4014892
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Schuppan D; Molz KH; Staib AH; Rietbrock N
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis.
Conway SP; Etherington C; Peckham DG; Brownlee KG; Whitehead A; Cunliffe H
J Antimicrob Chemother; 2004 May; 53(5):841-7. PubMed ID: 15044430
[TBL] [Abstract][Full Text] [Related]
17. Montelukast pharmacokinetics in cystic fibrosis.
Graff GR; Weber A; Wessler-Starman D; Smith AL
J Pediatr; 2003 Jan; 142(1):53-6. PubMed ID: 12520255
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of three sustained-release theophylline preparations (Theograd, 350 mg Theolair Retard, and 300 mg Theolin Retard) in steady state in six normals and six patients with chronic asthmatic bronchitis--Part II: Lung function.
van der Vet AP; Kreukniet J; Drost RH; Maes RA
Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):339-44. PubMed ID: 4030161
[TBL] [Abstract][Full Text] [Related]
19. Serum theophylline profile with once-daily theophylline (Uniphyl) following conversion from intravenous theophylline in adult asthmatic patients.
Fradette M; Babich M; Friesen EG; Archibald JS; Babul N
Clin Ther; 1994; 16(2):160-8. PubMed ID: 8062311
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of theophylline in children with acute asthmatic crisis].
Casasín Edo T; Llusa Arbos M; Gómez Papi A; Closa Monasterolo R; Tarrés Roure A
An Esp Pediatr; 1988 Sep; 29(3):220-2. PubMed ID: 3057979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
